Chapter Two - A Drug Like No Other

CHAPTER TWO

A Drug Like No Other

EVERY DRUG HAS a story.

Some begin in labs. Others in folklore. OxyContin started in a boardroom.

By the early 1990s, Purdue Pharma was a modest company. It had sold laxatives, earwax removers, and painkillers. But it wanted something bigger. A flagship. A blockbuster. A product that could move billions, not just bottles.

So the team focused on an old molecule with new potential: oxycodone.

Oxycodone wasn’t new. It had been around since the 1910s. It was powerful, effective, and addictive. Everyone knew that. But Purdue’s plan wasn’t to invent a new drug.

It was to repackage an old one and rewrite the narrative around it.

Their idea was simple: take oxycodone, slap it inside a time-release shell, and call it OxyContin. The coating would slowly dissolve over twelve hours, theoretically making the drug less prone to abuse. Fewer highs. Less addiction. That was the pitch.

Except it wasn’t true.

Internally, Purdue knew that time-release didn’t eliminate the risk. They also knew users could easily crush the pill to bypass the coating, releasing the full dose all at once. A chemical bomb of pure oxycodone. Early tests showed it. Sales reps knew it. Executives were warned.

But instead of pulling back, Purdue went full throttle.

They marketed OxyContin as “less addictive” than immediate-release opioids. Not because they had proof, but because they had a story. And stories sell.

They trained reps to tell doctors that the slow-release formula reduced abuse. They printed brochures and ran ads with smiling patients. They coined terms like “breakthrough pain” and “pseudoaddiction,” language designed to make doctors feel safe prescribing stronger opioids, more often, to more people.

And in 1996, Oxy hit the market like a silent missile.

It wasn’t flashy. No national news coverage. No public rollout. Just a slow flood of samples, sales calls, and incentives. A drug that looked like medicine. Felt like relief. And acted like heroin.

Doctors bought in. Patients trusted them. Pharmacies stocked it. And Purdue?

They kept the engine running.

Because they hadn’t just invented a drug.
They’d invented a narrative.

Oxy wasn’t addictive. It was misunderstood.

The people suffering weren’t overdosing. They were misusing.

The problem wasn’t the pill. It was the patient.

This was the lie at the heart of the campaign and the secret that would unravel the country.